Financing ·
Virax Biolabs Group Limited entered into an inducement letter agreement on July 9, 2026, to facilitate the exercise of…
VRAXVirax Biolabs Group Ltd
Virax Biolabs Group Limited entered into an inducement letter agreement on July 9, 2026, to facilitate the exercise of existing warrants and preferred investment options at a reduced exercise price of $6.00 per share. The company received approximately $3.3 million in gross proceeds from the holder's exercise of existing warrants. In exchange, the company will issue new Series A and Series B preferred investment options to purchase up to 1,096,000 ordinary shares. Virax Biolabs Group Limited is a biotechnology company focused on vaccine and diagnostic products.